MDMilan Dusik

Milan Dusik

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Milan Dusik has a total of 88 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prehospital extracorporeal cardiopulmonary resuscitation for refractory out-of-hospital cardiac arrest: a protocol for the Rapid prehospital ACcess to ECPR in Prague (RACE Prague) single-arm pilot feasibility study

    by Daniel Rob, Silvie Trhlíková, Jan Pudil, Petra Kaválková, Klaudia Sviteková, Eliška Mocková, Milan Dusík, Jaromír Macoun, Tereza Frýbová, Jaromír Fichtl, et al.

  • Open Access

    Sex differences in management and outcomes after out-of-hospital cardiac arrest with angiographically confirmed obstructive coronary artery disease

    by Klaudia Svitekova, Daniel Rob, Eliska Mockova, Petra Kavalkova, Jan Pudil, Milan Dusik, Jaromir Macoun, Eva Svobodova, Jan Malik, Anna Valerianova, et al.

  • Open Access

    Effect of Weight Loss Amplitude Combined with Antiarrhythmic Drugs on Atrial Fibrillation Freedom, as compared to Catheter Ablation: A Sub-Analysis of the PRAGUE-25 Trial

    by Dalibor Heřman, Jana Veselá, Tomas Roubicek, Stepan Havranek, Jan Chovancik, Veronika Bulkova, Marek Hozman, Ivan Ranic, Jana Hozmanova, Martin Matoulek, et al.

    Background and Aims: In the PRAGUE-25 study, the effect of lifestyle modification (LFM) in combination with antiarrhythmic drugs (AAD) in patients with atrial fibrillation (AF) and BMI 30-40 was smaller than that of catheter ablation (CA). The presented sub-analysis aims to assess the relationship between the actual weight reduction and the AF burden 12 months after randomization. Methods: Per-protocol analysis of the PRAGUE-25 trial. Patients in the LFM+AAD group were stratified into tertiles based on the extent of relative weight reduction, and a comparison of AF burden was performed between the LFM+AAD tertiles and the CA group. Results: The study analyzed 83 LFM+AAD patients (age 60 ±9 years, 31% women, 54% paroxysmal AF, mean weight 109±17 kg) and 99 CA patients (age 60±9 years, 32% women, 56% paroxysmal AF, weight 109±15 kg). Within the LFM+AAD group, 28 patients achieved a weight reduction of >8.3% (−15.46±6.16 kg), 27 patients were between 3.1–8.1% (−6.56±2.28 kg), and 28 patients were <3.1% (+1.38±4.03 kg). Compared to the CA group, the AF burden at 12 months (0 [IQR 0–0]) was significantly higher in the second (3.5% [0; 52] and third (1[0; 47] LFM-ADD tertiles, but did not differ from CA in the first tertile (0% [0; 11.], p=0.17). Conclusion: In obese patients, the maintenance of SR on AADs is related to the level of weight reduction. The efficacy of AADs in obese patients with a significant weight loss at 12-months follow-up is close to catheter ablation, although the overall AF burden is still non-significantly higher.


  • Open Access

    Catheter ablation in patients on mechanical circulatory supports for cardiogenic shock

    by Milan Dusik, Stepan Havranek, Daniel Rob, Jan Simek, Martin Valek, Zdenka Fingrova, Tomas Boucek, Jan Pudil, Ales Linhart, Jan Belohlavek

    Short-term mechanical circulatory supports (MCS) are used to stabilize patients with severe cardiogenic shock (CS). Catheter ablation may be an option to suppress recurrent arrhythmias preventing MCS weaning. We retrospectively analysed a dedicated registry to identify CS patients who underwent a catheter ablation between January 2020 and August 2024 for treatment resistant and hemodynamically significant arrhythmias while being on the MCS. Patients with supraventricular and ventricular tachycardias (SVT/VT) were analysed separately. Nine patients (8 males, 69 [IQR 60;74] years) were ablated for a refractory VT. Impella CP was used in 6 patients, VA ECMO in 2 patients, and 1 patient was on ECPELLA. Seven patients (78%) were successfully weaned off the MCS after the catheter ablation. 3 patients (33%) died within 30 days. The arrhythmia recurred in 5 patients (56%). Significant complications of MCS were reported in 6 patients (66%). The catheter ablation was complicated in one patient. SVT ablation was performed in 4 patients (3 males, 73 [IQR 67; 78] years, 1x VA ECMO, 2x Impella CP, 1x Impella 5.5). Three patients with atrial fibrillation were treated by a non-selective AV node ablation (pace and ablate strategy). One patient underwent an ablation of focal atrial tachycardia. The MCS was successfully explanted in all patients and no patient died in 30 days. The MCS use was complicated in one patient. Catheter ablation of refractory arrhythmias in CS patients treated by MCS is a safe and feasible approach to facilitate the MCS weaning process.


  • Open Access

    Cardiac Rhythm Conversions and the Outcome in Refractory Out-of-Hospital Cardiac Arrest: Extracorporeal Versus Conventional Resuscitation

    by Stepan Havranek, Jakub Neuhöfer, Michaela Vesela, Petra Kavalkova, Daniel Rob, Zdenka Msc Fingrova, Jana Smalcova, Ondrej Franek, Michal Msc Huptych, Milan Dusik, et al.

    OBJECTIVES: A Prague out-of-hospital cardiac arrest (OHCA) study has demonstrated that an invasive approach (early transport to the hospital, extracorporeal cardiopulmonary resuscitation [ECPR]) is a feasible and effective treatment strategy in refractory OHCA. This post hoc analysis of the Prague OHCA study aimed to stratify the prognosis of patients according to the detailed course of heart rhythm during prehospital and early hospital periods. DESIGN, SETTING, AND PATIENTS: This analysis included all 256 patients (median age 58, 17% females) randomized to the Prague OHCA study. The sequence of heart rhythms during the prehospital period was analyzed in terms of neurologic outcomes after 180 days. The primary outcome was a composite of survival with Cerebral Performance Category 1 or 2 at 180 days. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Within the study cohort, 156 (61%) manifested ventricular fibrillation (VF), 45 pulseless electrical activity, and 55 asystole as the initial rhythm. Patients with an initial VF who reached a sustained recovery of spontaneous circulation (ROSC) had the highest proportion of reaching a primary outcome (32/44 [73%]). Patients who had one or more episodes of asystole during cardiopulmonary resuscitation had the lowest rate of primary endpoint (5/39 [13%]). Patients who experienced intermittent ROSC showed a higher success rate in achieving the primary outcome when treated with an invasive-based approach (including ECPR) compared with the conventional strategy (26/34 [76%] vs. 24/50 [48%]; p < 0.05). CONCLUSIONS: Achieving ROSC is the best prognostic marker in OHCA patients with an initially refractory VF. Patients with intermittent ROSC after the initial VF and ongoing VF seem to be optimal candidates for an invasive approach. Asystole detection at any time during resuscitation is a strong negative prognostic marker, irrespective of the initial rhythm.


  • Open Access

    Ventricular arrhythmias associated with electrical cardioversion for atrial fibrillation, a multicenter study

    by O Tovia Brodie, M Rav Acha, F Bayya, S Havranek, M Dusik, L Rivetti, R Mantovan, A Sabbag, P E Lazzerini, L Bertolozzi, et al.

    Background: Cases of ventricular arrhythmias (VAs) associated with QT prolongation after electrical cardioversion (ECV) for atrial fibrillation have been reported. Purpose: To assess the incidence, timing and clinical characteristics of patients with VAs post-ECV for AF. Methods: This is a multicenter international study. Seventy-seven centers were approached. Data was received from 13 worldwide centers. VAs included were torsades de pointes (TdP), NSPVT>3 beats or SCD within 7 days of ECV. The total number of ECVs performed at each center during the time period for which data was sent was provided. Results: VAs occurred after ECV at an estimated incidence of 0.16%, range 0- 1.3% at different centers. Twenty-three patients with VAs were identified from 8 European centers, from 2008-2023, of whom 18 (78%) were from 2019-2023. There were 13 (56.5%) females, aged 71+11 years, mean LVEF=45+9%. AF duration prior to ECV was 72+65 days. Antiarrhythmic drugs (AADs) used prior to ECV were amiodarone in 9 (39%), sotalol in 4 (17%), class Ic in 3 (13%), beta blockers in 19 (83%), CCB in 1(4%) and digoxin in 4 (17%) patients. Five (22%) patients received QT prolonging drugs other then AADs. Baseline hypokalemia 3 beats in 5(22%) and 1(4%) SCD. Arrhythmia documentation was available in 19 (83%) patients. Baseline mean HR pre-ECV was 115+30bpm and QT 388+61ms, both significantly differed from post-ECV mean HR which was 58+11bpm and QT 469+63ms, P<0.0001. Arrhythmia occurred 45+54 hours post-ECV, median 28.5 hours, range 5 minutes- 10 days. Figure 1 demonstrates an example of serial ECG changes from baseline to TdP occurrence. An arrhythmic storm occurred in 11 (48%) patients. Arrhythmia reoccurred in 9 (39%) patients, mean 13.25 + 15 (range 0.5-48) hours after the index event. The arrhythmias which reoccurred were TdP in 5 (22%), VF in 2 (9%), NSPVT in 1 (4%) and monomorphic VT in 1 (4%) patient. Acute therapy with DCCV was needed in 10 (43%) patients. AADs were discontinued in 16 patients. IV electrolytes were helpful in arrhythmia control in 16 (89%) of 18 patients, IV isoproterenol was helpful in 1 (25%) of 4 patients, temporary pacing with arrhythmia control in 2(40%) of 5 patients in whom it was used. ICD was implanted in 7 patients and a pacemaker in 4 others. Two (8.7%) patients expired, 1 died suddenly at home 12 hours after ECV and 1 suffered from acute heart failure and fatal TdP 72 hours after ECV while hospitalized. Conclusion: VAs associated with QT prolongation after ECV for AF occur mainly 24-48 hours after ECV and may reoccur. Prolonged monitoring prior to discharge should be considered for prevention of fatal outcomes in patients with any evidence of QT prolongation following ECV.Figure 1

  • Open Access

    Serum lactate in refractory out-of-hospital cardiac arrest: Post-hoc analysis of the Prague OHCA study

    by Milan Dusik, Daniel Rob, Jana Smalcova, Stepan Havranek, Jiri Karasek, Ondrej Smid, Helena Lahoda Brodska, Petra Kavalkova, Michal Huptych, Jan Bakker, et al.


  • Open Access

    Catheter ablation of atrial fibrillation and atrial tachycardia in patients with pulmonary hypertension: a randomised study

    by S Havranek, Z Fingrova, T Skala, A Reichenbach, M Dusik, P Jansa, D Ambroz, V Dytrych, D Wichterle

    Funding Acknowledgements: Type of funding sources: Public grant(s) – National budget only. Main funding source(s): The study was supported by the Ministry of Health of the Czech Republic. Background: Atrial fibrillation (AF) and other atrial tachycardias (ATs), including typical atrial flutter (AFL), are common in patients with pulmonary hypertension. Frequently, several supraventricular arrhythmias are successively observed in individual patients. Purpose: We investigated the hypothesis of whether more extensive radiofrequency catheter ablation of the bi-atrial arrhythmogenic substrate instead of clinical arrhythmia ablation alone results in superior clinical outcomes in patients with PH and AF / AT. Methods: Patients with combined post- and pre-capillary or isolated pre-capillary PH and AF / AT indicated to catheter ablation were enrolled in 3 centers and randomized 1:1 into two parallel treatments arms: (A) Clinical arrhythmia ablation and (B) Clinical arrhythmia plus substrate-based ablation. The primary endpoint was arrhythmia recurrence >30 s without antiarrhythmic drugs after the 3-month blanking period. Results: A total of 77 patients (mean age 67 ± 10 years; 41 males) were enrolled. The presumable clinical arrhythmia was AF in 38 and AT in 36 patients, including typical AFL in 23 patients. During the median follow-up period of 13 (IQR: 12; 19) months, the primary endpoint occurred in 15 patients (42 %) vs. 17 patients (45 %) in the group B vs. A (hazard ratio: 0.97, 95% confidence interval: 0.49-2.0). There was no excess of procedural complications and clinical follow-up events including an all-cause death in group B. Conclusion: Extensive ablation, compared with a limited approach, was not beneficial in terms of arrhythmia recurrence in patients with AF / AT and pulmonary hypertension.

  • AB-452666-2 CATHETER ABLATION OF ATRIAL FIBRILLATION AND ATRIAL TACHYCARDIA IN PATIENTS WITH PULMONARY HYPERTENSION: A RANDOMISED STUDY

    by Stepan Havranek, Zdenka Fingrova, Tomas Skala, Adrian Reichenbach, Milan Dusik, Pavel Jansa, Dan Wichterle

  • Open Access

    PO-02-099 RADIOFREQUENCY CATHETER ABLATION OF ATRIAL TACHYCARDIA AND ATRIAL FIBRILLATION IN PATIENTS WITH PULMONARY HYPERTENSION. A SUBANALYSIS OF A PROSPECTIVE RANDOMIZED TRIAL

    by Stepan Havranek, Zdenka Fingrova, Tomas Skala, Adrian Reichenbach, Milan Dusik, Pavel Jansa, Dan Wichterle